5-Chloroindoloyl glycine amide inhibitors of glycogen phosphorylase: synthesis, in vitro, in vivo, and X-ray crystallographic characterization.
Wright SW,
Rath VL,
Genereux PE,
Hageman DL,
Levy CB,
McClure LD,
McCoid SC,
McPherson RK,
Schelhorn TM,
Wilder DE,
Zavadoski WJ,
Gibbs EM,
Treadway JL.
Pfizer Global Research and Development, Eastern Point Road, Groton, CT 06340, USA. stephen_w_wright@groton.pfizer.com
The synthesis, in vitro, and in vivo biological characterization of a series of achiral 5-chloroindoloyl glycine amide inhibitors of human liver glycogen phosphorylase A are described. Improved potency over previously reported compounds in cellular and in vivo assays was observed. The allosteric binding site of these compounds was shown by X-ray crystallography to be the same as that reported previously for 5-chloroindoloyl norstatine amides.
PMID: 15603973 [PubMed - indexed for MEDLINE]